Global Peptide Cancer Vaccine Market Analysis and Forecast 2024-2030

Global Peptide Cancer Vaccine Market Analysis and Forecast 2024-2030


Summary

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.

According to APO Research, The global Peptide Cancer Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Peptide Cancer Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Peptide Cancer Vaccine include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech and Generex Biotechnology, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Peptide Cancer Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Peptide Cancer Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Peptide Cancer Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Cancer Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Peptide Cancer Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Peptide Cancer Vaccine sales, projected growth trends, production technology, application and end-user industry.

Peptide Cancer Vaccine segment by Company

Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Peptide Cancer Vaccine segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Peptide Cancer Vaccine segment by Application

Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Peptide Cancer Vaccine segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Peptide Cancer Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Cancer Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.


1 Market Overview
1.1 Product Definition
1.2 Peptide Cancer Vaccine Market by Pipeline
1.2.1 Global Peptide Cancer Vaccine Market Size by Pipeline, 2019 VS 2023 VS 2030
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Peptide Cancer Vaccine Market by Application
1.3.1 Global Peptide Cancer Vaccine Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Peptide Cancer Vaccine Market Dynamics
2.1 Peptide Cancer Vaccine Industry Trends
2.2 Peptide Cancer Vaccine Industry Drivers
2.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
2.4 Peptide Cancer Vaccine Industry Restraints
3 Global Market Growth Prospects
3.1 Global Peptide Cancer Vaccine Revenue Estimates and Forecasts (2019-2030)
3.2 Global Peptide Cancer Vaccine Revenue by Region
3.2.1 Global Peptide Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Peptide Cancer Vaccine Revenue by Region (2019-2024)
3.2.3 Global Peptide Cancer Vaccine Revenue by Region (2025-2030)
3.2.4 Global Peptide Cancer Vaccine Revenue Market Share by Region (2019-2030)
3.3 Global Peptide Cancer Vaccine Sales Estimates and Forecasts 2019-2030
3.4 Global Peptide Cancer Vaccine Sales by Region
3.4.1 Global Peptide Cancer Vaccine Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Peptide Cancer Vaccine Sales by Region (2019-2024)
3.4.3 Global Peptide Cancer Vaccine Sales by Region (2025-2030)
3.4.4 Global Peptide Cancer Vaccine Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 Market Competitive Landscape by Manufacturers
4.1 Global Peptide Cancer Vaccine Revenue by Manufacturers
4.1.1 Global Peptide Cancer Vaccine Revenue by Manufacturers (2019-2024)
4.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Peptide Cancer Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Peptide Cancer Vaccine Sales by Manufacturers
4.2.1 Global Peptide Cancer Vaccine Sales by Manufacturers (2019-2024)
4.2.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Peptide Cancer Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Peptide Cancer Vaccine Sales Price by Manufacturers (2019-2024)
4.4 Global Peptide Cancer Vaccine Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Peptide Cancer Vaccine Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Peptide Cancer Vaccine Manufacturers, Product Type & Application
4.7 Global Peptide Cancer Vaccine Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Peptide Cancer Vaccine Market CR5 and HHI
4.8.2 2023 Peptide Cancer Vaccine Tier 1, Tier 2, and Tier 3
5 Peptide Cancer Vaccine Market by Type
5.1 Global Peptide Cancer Vaccine Revenue by Type
5.1.1 Global Peptide Cancer Vaccine Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Peptide Cancer Vaccine Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Type (2019-2030)
5.2 Global Peptide Cancer Vaccine Sales by Type
5.2.1 Global Peptide Cancer Vaccine Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Peptide Cancer Vaccine Sales by Type (2019-2030) & (K Doses)
5.2.3 Global Peptide Cancer Vaccine Sales Market Share by Type (2019-2030)
5.3 Global Peptide Cancer Vaccine Price by Type
6 Peptide Cancer Vaccine Market by Application
6.1 Global Peptide Cancer Vaccine Revenue by Application
6.1.1 Global Peptide Cancer Vaccine Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Peptide Cancer Vaccine Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2019-2030)
6.2 Global Peptide Cancer Vaccine Sales by Application
6.2.1 Global Peptide Cancer Vaccine Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Peptide Cancer Vaccine Sales by Application (2019-2030) & (K Doses)
6.2.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2019-2030)
6.3 Global Peptide Cancer Vaccine Price by Application
7 Company Profiles
7.1 Boston Biomedical
7.1.1 Boston Biomedical Comapny Information
7.1.2 Boston Biomedical Business Overview
7.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
7.1.5 Boston Biomedical Recent Developments
7.2 Ultimovacs
7.2.1 Ultimovacs Comapny Information
7.2.2 Ultimovacs Business Overview
7.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
7.2.5 Ultimovacs Recent Developments
7.3 BrightPath Biotherapeutics
7.3.1 BrightPath Biotherapeutics Comapny Information
7.3.2 BrightPath Biotherapeutics Business Overview
7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
7.3.5 BrightPath Biotherapeutics Recent Developments
7.4 TapImmune
7.4.1 TapImmune Comapny Information
7.4.2 TapImmune Business Overview
7.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
7.4.5 TapImmune Recent Developments
7.5 Immatics
7.5.1 Immatics Comapny Information
7.5.2 Immatics Business Overview
7.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
7.5.5 Immatics Recent Developments
7.6 Sellas
7.6.1 Sellas Comapny Information
7.6.2 Sellas Business Overview
7.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
7.6.5 Sellas Recent Developments
7.7 Imugene
7.7.1 Imugene Comapny Information
7.7.2 Imugene Business Overview
7.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
7.7.5 Imugene Recent Developments
7.8 VAXON Biotech
7.8.1 VAXON Biotech Comapny Information
7.8.2 VAXON Biotech Business Overview
7.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
7.8.5 VAXON Biotech Recent Developments
7.9 Generex Biotechnology
7.9.1 Generex Biotechnology Comapny Information
7.9.2 Generex Biotechnology Business Overview
7.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
7.9.5 Generex Biotechnology Recent Developments
7.10 ISA Pharmaceuticals
7.10.1 ISA Pharmaceuticals Comapny Information
7.10.2 ISA Pharmaceuticals Business Overview
7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
7.10.5 ISA Pharmaceuticals Recent Developments
7.11 OncoTherapy Science
7.11.1 OncoTherapy Science Comapny Information
7.11.2 OncoTherapy Science Business Overview
7.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
7.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
7.11.5 OncoTherapy Science Recent Developments
8 North America
8.1 North America Peptide Cancer Vaccine Market Size by Pipeline
8.1.1 North America Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
8.1.2 North America Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
8.1.3 North America Peptide Cancer Vaccine Price by Pipeline (2019-2030)
8.2 North America Peptide Cancer Vaccine Market Size by Application
8.2.1 North America Peptide Cancer Vaccine Revenue by Application (2019-2030)
8.2.2 North America Peptide Cancer Vaccine Sales by Application (2019-2030)
8.2.3 North America Peptide Cancer Vaccine Price by Application (2019-2030)
8.3 North America Peptide Cancer Vaccine Market Size by Country
8.3.1 North America Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Peptide Cancer Vaccine Price by Country (2019-2030)
8.3.4 U.S.
8.3.5 Canada
9 Europe
9.1 Europe Peptide Cancer Vaccine Market Size by Pipeline
9.1.1 Europe Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
9.1.2 Europe Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
9.1.3 Europe Peptide Cancer Vaccine Price by Pipeline (2019-2030)
9.2 Europe Peptide Cancer Vaccine Market Size by Application
9.2.1 Europe Peptide Cancer Vaccine Revenue by Application (2019-2030)
9.2.2 Europe Peptide Cancer Vaccine Sales by Application (2019-2030)
9.2.3 Europe Peptide Cancer Vaccine Price by Application (2019-2030)
9.3 Europe Peptide Cancer Vaccine Market Size by Country
9.3.1 Europe Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Peptide Cancer Vaccine Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 China
10.1 China Peptide Cancer Vaccine Market Size by Pipeline
10.1.1 China Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
10.1.2 China Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
10.1.3 China Peptide Cancer Vaccine Price by Pipeline (2019-2030)
10.2 China Peptide Cancer Vaccine Market Size by Application
10.2.1 China Peptide Cancer Vaccine Revenue by Application (2019-2030)
10.2.2 China Peptide Cancer Vaccine Sales by Application (2019-2030)
10.2.3 China Peptide Cancer Vaccine Price by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Peptide Cancer Vaccine Market Size by Pipeline
11.1.1 Asia Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
11.1.2 Asia Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
11.1.3 Asia Peptide Cancer Vaccine Price by Pipeline (2019-2030)
11.2 Asia Peptide Cancer Vaccine Market Size by Application
11.2.1 Asia Peptide Cancer Vaccine Revenue by Application (2019-2030)
11.2.2 Asia Peptide Cancer Vaccine Sales by Application (2019-2030)
11.2.3 Asia Peptide Cancer Vaccine Price by Application (2019-2030)
11.3 Asia Peptide Cancer Vaccine Market Size by Country
11.3.1 Asia Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Peptide Cancer Vaccine Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 Middle East, Africa and Latin America
12.1 MEALA Peptide Cancer Vaccine Market Size by Pipeline
12.1.1 MEALA Peptide Cancer Vaccine Revenue by Pipeline (2019-2030)
12.1.2 MEALA Peptide Cancer Vaccine Sales by Pipeline (2019-2030)
12.1.3 MEALA Peptide Cancer Vaccine Price by Pipeline (2019-2030)
12.2 MEALA Peptide Cancer Vaccine Market Size by Application
12.2.1 MEALA Peptide Cancer Vaccine Revenue by Application (2019-2030)
12.2.2 MEALA Peptide Cancer Vaccine Sales by Application (2019-2030)
12.2.3 MEALA Peptide Cancer Vaccine Price by Application (2019-2030)
12.3 MEALA Peptide Cancer Vaccine Market Size by Country
12.3.1 MEALA Peptide Cancer Vaccine Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Peptide Cancer Vaccine Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Peptide Cancer Vaccine Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 Value Chain and Sales Channels Analysis
13.1 Peptide Cancer Vaccine Value Chain Analysis
13.1.1 Peptide Cancer Vaccine Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Peptide Cancer Vaccine Production Mode & Process
13.2 Peptide Cancer Vaccine Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Peptide Cancer Vaccine Distributors
13.2.3 Peptide Cancer Vaccine Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings